title: Safety, formulation, and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1.
abstract: In the present study the antiviral properties of the bacteriocin subtilosin against Herpes simplex virus type 1 (HSV-1) and the safety and efficacy of a subtilosin-based nanofiber formulation were determined. High concentrations of subtilosin, the cyclical antimicrobial peptide produced by Bacillus amyloliquefaciens, were virucidal against HSV-1. Interestingly, at non-virucidal concentrations, subtilosin inhibited wild type HSV-1 and aciclovir-resistant mutants in a dose-dependent manner. Although the exact antiviral mechanism is not fully understood, time of addition experiments and western blot analysis suggest that subtilosin does not affect viral multiplication steps prior to protein synthesis. Poly(vinyl alcohol) (PVOH)-based subtilosin nanofibers with a width of 278 nm were produced by the electrospinning process. The retained antimicrobial activity of the subtilosin-based fibers was determined via an agar well diffusion assay. The loading capacity of the fibers was 2.4 mg subtilosin/g fiber, and loading efficiency was 31.6%. Furthermore, the nanofibers with and without incorporated subtilosin were shown to be nontoxic to human epidermal tissues using an in vitro human tissue model. Taking together these results subtilosin-based nanofibers should be further studied as a novel alternative method for treatment and/or control of HSV-1 infection.
authors: Laboratorio de Virología. Departamento de Química Biológica. Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Piso 4, 1428, Buenos Aires, Argentina.
authors: Nicolás I
authors: NI
authors: Torres
authors: Katia Sutyak
authors: KS
authors: Noll
authors: Shiqi
authors: S
authors: Xu
authors: Ji
authors: J
authors: Li
authors: Qingrong
authors: Q
authors: Huang
authors: Patrick J
authors: PJ
authors: Sinko
authors: Mónica B
authors: MB
authors: Wachsman
authors: Michael L
authors: ML
authors: Chikindas
keywords: antiviral; bacteriocin; nanofiber; subtilosin
references: Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):187-94
references: 10795591
references: J Protein Chem. 2001 Aug;20(6):501-6
references: 11760125
references: J Med Virol. 2002 Feb;66(2):229-34
references: 11782932
references: Antiviral Res. 2001 Aug;51(2):141-9
references: 11431038
references: Lancet. 2001 May 12;357(9267):1513-8
references: 11377626
references: Probiotics Antimicrob Proteins. 2010 Mar;2(1):46-51
references: 26780900
references: J Immunol Methods. 1986 May 22;89(2):271-7
references: 3486233
references: Antivir Chem Chemother. 2000 Jan;11(1):71-7
references: 10693656
references: J Clin Virol. 2001 Jun;21(3):261-9
references: 11397663
references: J Am Acad Dermatol. 2007 Nov;57(5):737-63; quiz 764-6
references: 17939933
references: Chemotherapy. 2006;52(1):38-42
references: 16340198
references: Bull World Health Organ. 2008 Oct;86(10):805-12, A
references: 18949218
references: Lancet. 2007 Dec 22;370(9605):2127-37
references: 18156035
references: Virology. 1993 Oct;196(2):548-56
references: 8396802
references: Appl Environ Microbiol. 2000 Apr;66(4):1298-304
references: 10742203
references: Lancet Neurol. 2007 Nov;6(11):1015-28
references: 17945155
references: J Biomed Biotechnol. 2010;2010:
references: 20798871
references: J Clin Microbiol. 2001 Mar;39(3):913-7
references: 11230403
references: FEMS Microbiol Rev. 2011 Jan;35(1):201-32
references: 20695901
references: J Clin Virol. 2003 Jan;26(1):29-37
references: 12589832
references: Lancet. 2012 Feb 18;379(9816):641-7
references: 22225814
references: Clin Microbiol Rev. 2006 Jul;19(3):491-511
references: 16847082
references: Chem Phys Lipids. 2005 Oct;137(1-2):38-51
references: 16095584
references: Clin Exp Ophthalmol. 2010 Apr;38(3):309-13
references: 20447128
references: Infect Dis Obstet Gynecol. 2008;2008:540758
references: 18923673
references: Appl Microbiol Biotechnol. 2004 Aug;65(3):268-72
references: 14963617
references: Appl Environ Microbiol. 1995 Jul;61(7):2643-8
references: 7618877
references: J Fam Plann Reprod Health Care. 2009 Oct;35(4):237-42
references: 19849918
references: Int J Antimicrob Agents. 2005 Jun;25(6):508-13
references: 15869868
references: Antiviral Res. 2003 Mar;58(1):17-24
references: 12719003
references: J Biochem. 1985 Sep;98(3):585-603
references: 3936839
references: Arch Neurol. 2008 May;65(5):596-600
references: 18474734
references: J Appl Microbiol. 2008 Apr;104(4):1067-74
references: 17976171
references: Int J Antimicrob Agents. 2004 Apr;23(4):382-9
references: 15081088
references: J Infect Dis. 2012 May 15;205(10):1539-43
references: 22457282
references: Int J Mol Sci. 2011;12(4):2158-73
references: 21731433
references: J Toxicol Environ Health A. 2011;74(19):1249-60
references: 21830855
references: Antimicrob Agents Chemother. 2011 Feb;55(2):459-72
references: 21078929
references: Dermatol Clin. 2003 Apr;21(2):311-20
references: 12757254
references: J Virol. 1985 May;54(2):467-72
references: 2985808
references: Viruses. 2009 Dec;1(3):939-64
references: 21994576
references: J Infect Dis. 1992 Feb;165(2):251-5
references: 1309846
references: J Gen Virol. 1998 Apr;79 ( Pt 4):731-40
references: 9568968
references: Ann Neurol. 2010 Jun;67(6):830-3
references: 20517946
references: N Engl J Med. 2010 Feb 4;362(5):427-39
references: 20089951
references: J Virol. 1986 Dec;60(3):1068-74
references: 3023659
references: Int J Antimicrob Agents. 1999 Aug;12(4):293-9
references: 10493605
references: Virus Res. 2005 Aug;111(2):108-19
references: 15951043
references: Euro Surveill. 2009 Nov 26;14(47):
references: 19941804
references: Biochem Biophys Res Commun. 1996 Feb 15;219(2):555-9
references: 8605026